<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316638</url>
  </required_header>
  <id_info>
    <org_study_id>W00101IV101</org_study_id>
    <nct_id>NCT03316638</nct_id>
  </id_info>
  <brief_title>A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>Ulysse</acronym>
  <official_title>Phase I/II Open Label Dose Escalation and Dose Expansion Study of Intravenous Infusion of W0101, an Antibody-drug Conjugate, in Patients With Advanced or Metastatic Solid Tumors. International, Multicenter, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly
      overexpressed in many cancers.

      The development of antibody-drug conjugates takes advantage of the specificity of the mAb
      while augmenting its ability to produce a cytotoxic effect. The expected benefits of
      antibody-drug conjugation are enhancement of cytotoxicity in target cells and limiting
      toxicities of cytotoxic drugs in normal tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a First In Human study, multicenter, open label study divided into 2 parts: an
      initial dose escalation phase (I) followed by expansion cohort(s) phase (II).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>2 Cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Specific Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Identification of Dose-limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Specific Adverse Events</measure>
    <time_frame>From first administration up to 63 days</time_frame>
    <description>Identification of Dose-limiting toxicities</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>W0101 - Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a 14 days treatment cycle cohort in a 2 weeks schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>W0101 - Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a 21 days treatment cycle cohort in a 3 weeks schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>W0101 - Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be initiated after completion of cohorts A1 and A2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>W0101 - Cohort A1</intervention_name>
    <description>Administered once every 2 weeks</description>
    <arm_group_label>W0101 - Cohort A1</arm_group_label>
    <other_name>Dose escalation Phase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>W0101 - Cohort A2</intervention_name>
    <description>Administered every 3 weeks</description>
    <arm_group_label>W0101 - Cohort A2</arm_group_label>
    <other_name>Dose escalation Phase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>W0101 - Expansion Phase</intervention_name>
    <description>Administered according to the recommended dose for expansion</description>
    <arm_group_label>W0101 - Expansion Phase</arm_group_label>
    <other_name>Expansion Phase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Dose escalation phase (cohort A1 and A2)

          1. Male or female subjects age ≥ 18 years

          2. Subjects with histologically or cytologically confirmed advanced or metastatic solid
             tumors (excluding lymphoma) , unresponsive to standard treatment or for whom no
             standard treatment is available or appropriate

          3. ECOG performance status 0 or 1

          4. Adequate bone marrow, renal, hepatic at screening and at Baseline

          5. Subject must have measurable diseases as per RECIST v1.1 criteria

        Exclusion Criteria:

          1. Symptomatic brain metastases, CNS tumors

          2. Symptomatic motor or sensory peripheral neuropathy (≥ grade 2)

          3. Subjects having ophthalmologic abnormalities

          4. Active serious systemic disease (infection,organic or dysmetabolic desease)

          5. Left ventricular ejection fraction (LVEF) &lt; 45% as determined by MUGA scan or
             echography at screening

          6. QTc &gt; 470 msec on screening ECG or congenital long QT syndrome

          7. Biologic therapy (including ADCs ≤ 4 weeks before first study treatment
             administration)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Keddad</last_name>
    <role>Study Director</role>
    <affiliation>Pierre Fabre Medicament</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Fabre Medicament</last_name>
    <phone>0033534506000</phone>
    <email>contact_essais_cliniques@pierre-fabre.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IUCT</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IGR</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VHIO</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

